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includes the synthesis of the intermediate compound, a 
hydroxymethyl-substituted enone. In addition, a method is 
provided for synthesizing inhibitors, Which includes PI‘ 
modi?ed analogues. These analogues selectively bind to a 
major immunoproteasome catalytic subunit LMP2 and inac 
tivate its proteolytic activity in a method of treating diseases, 
including myeloma and other cancers, Huntington’s disease 
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EPOXYKETONE-BASED 
IMMUNOPROTEASOME INHIBITORS 
FIELD OF THE INVENTION 
The present method relates to epoxyketone-based immu 
noproteasome inhibitors and, in particular, to the synthesis of 
the inhibitors, their intermediaries, and treatment of disease 
using the inhibitors. 
BACKGROUND OF THE INVENTION 
Intracellular protein degradation is a highly regulated pro 
cess in Which proteins are ?rst targeted for degradation by 
conjugation to ubiquitin, a 76 amino acid polypeptide. Ubiq 
uitinated proteins are then recogniZed by the 19S regulatory 
domain of the 26S proteasome. Through a series of ATP 
hydrolysis-dependent processes, targeted proteins are deu 
biquitinated and threaded into the core proteolytic complex, 
the 20S proteasome, Where they are degraded into small pep 
tides. Interestingly, exposure of cells to stimuli, such as inter 
feron (IFN)-y, factor (TNF)-0t and 
lipopolysaccharide (LPS), induces the synthesis of certain 
catalytic subunits (LMP2, MECL-l and LMP7) that together 
are incorporated into alternative proteasome form, knoWn as 
the immunoproteasome. 
tumor necrosis 
The immunoproteasome, as compared to the constitutive 
proteasome, has an enhanced capacity to generate peptides 
bearing hydrophobic andbasic amino acids at their C-termini, 
and a reduced capacity to produce peptides bearing acidic 
residues at their C-terminus. Consequently, the spectrum of 
the produced peptides is shifted toWards peptides Which asso 
ciate With MHC class I molecules With increased a?inity, 
implicating a major role in antigen presentation. Immunopro 
teasome may be involved in some pathological processes, 
such as diabetes and autoimmune diseases. Therefore, devel 
opment of immunoproteasome-speci?c inhibitors Would be 
useful to investigate the role of immunoproteasome and to 
determine Whether immunoproteasome is a potential target 
for development of pharmaceutical agents. 
Scheme 1. ot',[3'-Epoxyketone linear peptide natural products, 
epoxomicin and eponemycin, and eponemycin analogues. 
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-continued 
Eponemycin (2) 
0 
Dihydroeponemycin (3) 
R I —CH2OH, R' I OH 
(4) R I alkyl, R' I C— or O— alkyl groups 
(5) R I CH3; R' I OH 
Anti -tumor natural products epoxomicin (l) and eponemy 
cin (2) are members of linear peptides containing ot',[3'-ep 
oxyketone pharmacophore and have been shoWn to exert their 
anticancer activity through proteasome inhibition. Of par 
ticular interest Was the ?nding that, despite structural simi 
larities, epoxomicin (l) and dihydroeponemycin (3), an 
active derivative of eponemycin, differ in their proteasome 
subunit binding speci?city. 
Moreover, unlike other classes of proteasome inhibitors 
that shoW non-target speci?city, the epoxyketone proteasome 
inhibitor is shoWn to be highly speci?c for the 20S protea 
some. The crystal structure of the yeast 20S proteasome com 
plexed With epoxomicin revealed that the unique speci?city 
of epoxyketone pharmacophore is contributed to the forma 
tion of an unusual 6-membered morpholino ring betWeen the 
amino terminal catalytic Thr-l of the 20S proteasome and the 
(ot',[3'-epoxyketone pharmacophore of epoxomicin, as shoWn 
in the mechanism beloW. 
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In addition, it has been shown that dihydroeponemycin (3) 
targets the subunits of both constitutive proteasome and 
immunoproteasome, Whereas epoxomicin (l) preferentially Schm“ihs?liii?sgifgiié?t?gggsgmtion of 
labels the catalytic subunits of the constitutive proteasome. ' 
Recent studies indicated that the ability of dihydroeponemy- 35 
cin to bind immunoproteasome subunits is attributed to the P3 
isooctanoic moiety of dihydroeponemycin but not the 
hydroxyl groups in the P2 and P1‘ positions (see scheme 1). RHN H 
Therefore, isooctanoic-based dihydroeponemycin analogue 
(4) or other dihydroeponemycin analogues having a linear 40 O \ 7 
hydrocarbon group at the P3 position may provide an oppor- / / \ 
LiJR 
OLi 
8 
tunity for the development of immunoproteasome-speci?c 
inhibitors. HoWever, a simple and practical approach for the 
synthesis of dihydroeponemycin has yet to be developed. 
Particularly, the lack of the e?icient synthetic approach for 
the hydroxymethyl-substituted enone motif has been a major H 
obstacle for e?icient synthesis of dihydroeponemycin and 
their Pl' derivatives (4). O O OH 
Over the years, a number of elegant synthetic strategies for 50 
the synthesis of eponemycin and dihydroeponemycin have / 
been developed. A key step in the synthesis is the preparation \ / 
of hydroxymethyl-substituted enone 10 (Scheme 2). In sev 
eral earlier approaches, the enone 10 Was prepared from the 
reaction of dilithio reagent 8 With the corresponding aldehyde 
(Scheme 2). HoWever, loW yields and extra steps involving 
protection, oxidation and deprotection of OH groups pre 
vented large scale preparation. In similar approaches, the 
Weinreb-type amide derivatives treated With dilithio reagent 60 
8 did not yield the desired hydroXymethyl-sub stituted enone 
10. More recently, neW synthetic approaches have been devel- OCH3 
oped based on the cinchona alkaloid-catalyzed Baylis-Hill 
man type reactions that yield the intermediate 7 or Stille 65 OH 0 
coupling of Fmoc-Leu-Cl With n-tributylvinyltin folloWed by 9 
modi?ed Baylis-Hillman reaction (Scheme 2). 
4s. m 
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However, multiple steps and loW yields associated With 
these approaches may not be ideal for e?icient derivatiZation 
or construction of small library of dihydroeponemycin ana 
logues for screening immunoproteasome-speci?c inhibitors. 
Over the past decades, the proteasome has emerged as a 
major player in many important signaling processes such as 
cell cycle progression, in?ammatory responses and develop 
ment. In particular, the fact that the orderly destruction of cell 
cycle regulatory proteins is critical to the control of cellular 
processes associated With cancer has led to development of 
proteasome inhibitors as anti-cancer agents, leading to a 
recent FDA approval of the ?rst proteasome inhibitor bor‘t 
eZomib for multiple myeloma. Typically, more than 80% of 
cellular proteins are targeted for recognition and subsequent 
degradation by the proteasome via the attachment of multiple 
ubiquitin molecules. 
The 208 core has a four-stacked ring structure With seven 
different subunits in each ring. The tWo inner rings each 
contain three catalytically active [3 subunits. The non-cata 
lytic tWo outer a rings form a gated channel for unfolded 
protein entry and a base for the regulatory complexes (198 or 
1 18), Which provide the speci?city of the polypeptide recog 
nition. 
The 208 proteasome has been shoWn to exhibit three major 
activities: a chymotrypsin-like (CT-L) activity that cleaves 
after large hydrophobic residues, a trypsin-like (T-L) activity 
that hydrolyZes after basic amino acids, and a caspase-like 
(C-L) activity that cleaves after acidic amino acids. TWo other 
less-characterized catalytic activities have also been ascribed 
to the proteasome: BrAAP, Which cleaves after branched 
chain amino acids, and SNAAP, Which cleaves after small 
neutral amino acids. Thus far, While most efforts are directed 
to develop proteasome inhibitors against chymotrypsin-like 
activity, a feW studies have been successful to design inhibi 
tors targeting other proteasomal activities, such as caspase 
like and trypsin-like activities. Although the CT-L activity of 
the proteasome has been shoWn to be largely responsible for 
the proteolytic function of the proteasome in vivo and in vitro, 
the contribution of other major activities remains to be deter 
mined. 
While the immunoproteasome is Widely knoWn to play a 
major role in MHC class-l antigen presentation, it is believed 
not to be solely responsible for antigen presentation as the 
constitutive proteasome also generates immunogenic 
epitopes. 
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Recently, intense investigation on the role of immunopro 
teasome in cells from non-immune system has been initiated 
based on a number of studies indicating that immunoprotea 
some subunits may be implicated in some pathological pro 
cesses, such as hematological cancers, autoimmune diseases 
and neurodegenerative diseases. For example, a high level of 
immunoproteasome has been detected in neurodegenerative 
human brains, Whereas the human brain has been historically 
considered as an immunologically privileged organ. Speci? 
cally, it has been shoWn that the immunoproteasome is more 
highly expressed in the brains of AlZheimer’s disease (AD) 
than in brains of non-demented elderly, Whereas its expres 
sion in young brains is negligible or absent. In addition, some 
studies indicated that the immunoproteasome may be 
involved in Huntington’s disease (HD) neurodegeneration. 
Multiple myeloma is also knoWn to express a high level of 
immunoproteasome due to its bone marroW microenviron 
ment Where it replicates. Recently borteZomib (V EL 
CADE®), the ?rst proteasome inhibitor Was approved by the 
FDA for the treatment of multiple myeloma. Despite this 
remarkable advancement, its clinical use is severely limited 
due to drug-related toxicities. Given this, speci?c inhibition 
of immunoproteasome should alloW selective killings of mul 
tiple myeloma cells While sparing other cells in body that are 
lacking or minimally expressing the immunoproteasome. 
Despite the potential role of immunoproteasome in these 
pathological disorders, its functions are still not clearly 
understood. Currently, there are no immunoproteasome spe 
ci?c inhibitors Which are therapeutic agents, targeting the 
immunoproteasome. Furthermore, the exact role of immuno 
proteasome in pathogenesis is not clearly understood, due 
largely to the lack of an appropriate molecular probe. 
Although some proteasome inhibitors currently exist that 
selectively target the immunoproteasome, and a sequence 
comparison of catalytic subunits from the constitutive and 
immunoproteasomes exhibits a high homology, structural 
information about active sites of immunoproteasome are not 
knoWn to date, hindering prior efforts toWards the design of 
immunoproteasome-speci?c inhibitors via rational design 
approach, to be therapeutic agents. 
Scheme 3. Structures of 0t’, [5’, —epoxyketone linear peptide natural 
products and dihydroeponemycin analogues. Tripeptide epoxyketones 
having a linear hydrocarbon chain at the P3 position has a higher 
specificity toWards immunoproteasome catalytic subunits than normal 
tetrapeptide epoxyketones such as epoxomicin. 
CH3 0 o 
I H O 
N N 
_ N . N CH3 
: o 
: Huk O I N. l g z N 
i : g H 
: 0 i = 0 OH 
'_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __| \OH 
Dihydroeponernycin (2) 
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Dihydroeponemycin analogues 
TWo natural product proteasome inhibitors, epoxomicin 
and eponemycin, are members of the ot',[3'-epoxyketone lin 
ear peptide family. It has been previously shown that, despite 
structural similarities, epoxomicin (l) and dihydroeponemy 
cin (2), an active derivative of eponemycin, considerably 
differ in their proteasome subunit binding speci?city. For 
example, dihydroeponemycin preferentially labels the cata 
lytic threonine residues of immunoproteasome subunit LMP2 
and to a lesser degree, the constitutive proteasome subunit X 
and immunoproteasome subunit LMP7. On the other hand, 
epoxomicin covalently modi?es the N-terminus catalytic 
threonine residues of both the constitutive proteasome (X & 
Z) and immunoproteasome (LMP7 & MECLl) to a similar 
extent. It has been shoWn that a relatively higher speci?city of 
dihydroeponemycin toWards the immunoproteasome sub 
units as compared to epoxomicin is due to a linear hydrocar 
bon residue at the N-terminus (i.e., isooctanoic group). 
Recently, it has been shoWn that serine at the P2 site can be 
replaced With alanine While maintaining the same subunit 
binding pattern as dihydroeponemycin. More interestingly, 
careful analysis of other reports indicates that a residue at the 
Pl' site may be an important determinant for immunoprotea 
some subunit binding. 
SUMMARY OF THE INVENTION 
The present invention is directed to a neW and improved 
route to the synthesis of a hydroxymethyl-substituted enone 
and dihydroeponemycin (3). 
The present invention is also directed to the synthesis of 
proteasome inhibitors that selectively target the immunopro 
teasome. These proteasome inhibitors comprises a variety of 
Pl'-modi?ed dihydroeponemycin analogues using easily 
available protecting groups. The present dihydroeponemycin 
analogues selectively bind to a major immunoproteasome 
catalytic subunit LMP2 and inactivate the proteolytic activity 
of immunoproteasome With high speci?city. The proteasome 
inhibitors are therapeutic agents Which selectively target the 
immunoproteasome, and thereby treat diseases, including 
cancer, AlZheimer’s disease and Huntington’s disease. 
The present invention, in one form thereof, relates to a 
method for synthesizing a hydroXymethyl-sub stituted enone, 
comprising (a) reacting Boc-Leu-OMe With dimethyl meth 
ylphosphonate treated With tert-butyllithium to form the com 
pound, 
BocNH P\ 
m 
15 
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65 
8 
and (b) adding CH2O and KZO3 to the product of step (a) and 
alloWing the reagents to react to produce the hydroxymethyl 
substituted enone, 
BocNH 
The present method, in a further, speci?c form thereof, 
further comprises (c) adding TBDMSCl, lmidaZole and 
CH2Cl2 to the hydroxymethyl-substituted enone from step 
(b); (d) adding benZonitrile, H2O2, i-Pr2EtN and CH3OH; (e) 
adding TFA and CH2Cl2; and (f) adding 
NH 
OH 
0 \OTBDPS, 
HBTU, HoBt, i-PRzEtN and CH2Cl2, folloWed by TBAF and 
THF to produce dihydroeponemycin, 
MPH 
O 
The present invention, in another form thereof, relates to a 
P1‘ modi?ed dihydroeponemycin analogue comprising 
O 
NH 
H 
O 
R2, O 
Where: 
R1 is CH3 or CH3OH; and R2 is OH, 
US 7,642,369 B2 
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$ 
. . . 10 
The present invention, in another form, thereof, relates to a 
In one speci?c compound, R1 is CH3 and R2 is 
method for manufacturing a P1‘ modi?ed dihydroeponemy O 
cin analogue, comprising (a) reacting a hydroXymethyl-sub- ii 
. / \ 
st1tuted enone, 
15 . 
The present invention, in yet another form thereof, relates 
to a method of inactivating enzymatic activity of catalytic 
subunit LMP2 of the immunoproteasome, comprising react 
ing a P1‘ modi?ed dihydroeponemycin analogue, 
BocNH (I) 
0 OH, 
25 
With 2-methoxyethoxymethyl chloride, i-PrZEtN, CH2Cl2; O O 
(b) adding benZonitrile, H202, i-PrZEtN, CH3OH; (c) adding NHA 
TFA, CH2C12; and (d) adding HBTU, HoBt, i-PrZEtN, 30 W NH 
CH2Cl2, and 0 111 R2 
0 Where R1 is CH3 or CH3OH; and R2 is OH, 
NHJK 35 o o 
= OH, 
5 O 
0 CH3 O/\O/, O/\O/\/ \, , 
O O 
40 | I. 
to produce Pl‘ modi?ed dihydroeponemycin analogue of for- / \ or Ph/ Sl\Ph 
mulal + i 
45 
(I) With the catalytic subunit LMP2. 
The present invention, in anther form thereof, relates to a 
method for treating disease by administering to a patient an 
effective amount of a dihydroeponemycin analogue having 
0 O 50 the formula 1 
NH A 
W = NH ? (I) 
O R] 0 R2, 
55 
Where: 0 
R1 is CH3 or CH3OH; and NHA 0 
R2 is OH, 60 W 5 NH 
0 Ii] 0 R2, 
0 O 
O/\O/ O/\O/\/O\ 65 Where: 
R1 is CH3 or CH3OH; and 
R2 is OH, 
US 7,642,369 B2 
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O O 
O O/\O/, O/\O/\/ \, U, or 
O 
i. 1
to bind to the LMP2 subunit of the immunoproteasome, 
thereby treating the disease. In various, speci?c further 
embodiments, the disease is selected from the group consist 
ing of myeloma, AlZheimer’s disease, and Huntington’s dis 
ease; and R1 is CH3 and R2 is 
O 
S. 
a: 
The present invention, in yet another form thereof, relates 
to a method of inactivating the immunoproteasome, compris 
ing administering to a patient in need of treatment thereof, an 
effective amount of a dihydroeponemycin analogue of for 
mula I, 
(I) 
O 
O 
NH 
W 5 NH 
O R2, 
Where R1 is CH3 or CH3OH; and R2 is OH, 
O O 
O 
o/\o/ , o/\o/\/ \, , 
O O 
l l l l 
to bind to LMP2 of the immunoproteasome, to thereby inac 
tivate the immunoproteasome. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a Western blot shoWing dihydroeponemycin bind 
ing to both constitutive- and immunoproteasome catalytic 
subunits, in accordance With the present invention; 
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FIG. 2(a) is a Western blot shoWing LMP7/X and LMP2 
protein bands are competed aWay by dihydroeponemycin (2) 
and its analogue (9), and FIG. 2(b) is a Western blot shoWing 
proteasome subunit (Z, MECLl, LMP7 and X) bands are 
e?iciently competed aWay by excess epoxomicin on Western 
blot, in accordance With the present invention; 
FIG. 3 is a Western blot shoWing compounds 10, 11 and 13 
do not selectively target proteasome subunits, and compound 
14 does not covalently modify proteasome subunits, in accor 
dance With the present invention; 
FIG. 4(a) is a Western blot depicting compounds 12 and 15 
selectively targeting the immunoproteasome subunit LMP2 
in EL4 cells, and FIG. 4(b) is a Western blot shoWing com 
pounds 12 and 15 do not covalently modify the proteasome 
subunits that are normally labeled by epoxomicin, indicating 
that these compounds do not target subunits such as Z, 
MECL-l, LMP7 and X, in accordance With the present inven 
tion; 
FIG. 5 is a Western blot depicting compounds 15 covalently 
modify the immunoproteasome subunit LMP2; and 
FIG. 6 is a plot shoWing inhibition of the immunoprotea 
some chymotrypsin-like activity by compound 15, in accor 
dance With the present invention. 
DETAILED DESCRIPTION 
The present invention is directed to a neW and improved 
route to the synthesis of the hydroXymethyl-sub stituted enone 
and dihydroeponemycin (3). The hydroxyl group, commonly 
present in both eponemycin and epoxomicin at the P2 posi 
tion, is not required for immunoproteasome binding. 
In addition, the present invention is directed to a method of 
synthesiZing dihydroeponemycin analogues having the gen 
eral formula I 
(I) 
O 0 R2 
Where 
R1 is CH3 or CH3OH, and 
R2 is OH, 
The present invention is also directed to a method of treat 
ment comprising administering to a patient in need to treat 
ment thereof, a therapeutically effective amount of a dihy 
droeponemycin analogue, having the general formula I, to 
US 7,642,369 B2 
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bind to the LMP2 subunit of the immunoproteasome, thereby 
treating the disease. The treated diseases include myeloma, 
AlZheimer’s disease, and Huntington’s disease. 
The preferred dose for administration of the immunopro 
teasome inhibitor, in accordance With the present invention, is 
that amount Which Will be effective in preventing or treating 
cancer, such as myeloma, AlZheimer’s disease, or Hunting 
ton’s disease, by loWering or inhibiting LMP2 catalytic activ 
ity, by binding to the LMP2 subunit, and one Would readily 
recogniZe that this amount Will vary greatly depending on the 
nature and extent of the disease and the condition of a patient. 
An “effective amount” of the inhibitor to be used in accor 
dance With the invention is intended to mean a nontoxic but 
suf?cient amount of the agent, such that the desired prophy 
lactic or therapeutic effect is produced. Thus, the exact 
amount of the inhibitor that is required Will vary from subject 
to subject, depending on the species, age, and general condi 
tion of the subject, the severity of the condition being treated, 
the particular carrier or adjuvant being used and its mode of 
administration, and the like. Similarly, the dosing regimen 
should also be adjusted to suit the individual to Whom the 
composition is administered and Will once again vary With 
age, Weight, metabolism, etc. of the individual. Accordingly, 
the “effective amount” of any particular inhibitor Will vary 
based on the particular circumstances, and an appropriate 
effective amount may be determined in each case of applica 
tion by one of ordinary skill in the art using only routine 
experimentation. 
The present method provides an e?icient, practical syn 
thetic strategy for the synthesis of hydroxymethyl-sub stituted 
enone and dihydroeponemycin. The present method starts 
With readily available Boc-Leu-OMe, Which Was prepared 
from the reaction of Boc-Leu-OH With iodomethane in DMF. 
The reaction of Boc-Leu-OMe With dimethyl methylphos 
phonate treated With t-butyllithium yielded compound 13. 
Finally, the combination of Wittig-Homer and Baylis-Hill 
man type one-pot reactions yielded the hydroxymethyl-sub 
stituted enone 14 in high yield (Scheme 4). 
Scheme 4. Reagents and conditions: (a) i. CH3PO(OCH3)2, BuLi, 
THF, -78° C., 2 h; ii. 12, THF, -78° C., 3 h; (b) CHZO, K2CO3, 
H2O,1t, 3 h; (c) TBDPSCl, lrnidazole, CHZCIZ, it, 24 h; 
(d) Benzonitrile, H202, i—Pr2EtN, MeOH, 0° C., 3 h; 
(e) TFA, CHZCIZ, it, 15 min; (f) i. 19. HBTU, HoBt, 
i-PrZEtN, CHZCIZ, 1t, 12 h; ii. TBAF, THF,1t, 10 min. 
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Dihydroeponemycin (3) 
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The resulting hydroxymethyl substituted enone Was 
treated With TBDPSCl to yield compound 15. Epoxidation of 
compound 15 With hydrogen peroxide afforded tWo epoxyke 
tone isomers 16 and 17 as a 1:15 mixture Which Were readily 
separated by ?ash column chromatography using an elution 
system (heXanes-ethyl acetate:10: 1, v/v). The isomer (2-(R) 
epoxide) 17, Which migrates faster than the 2-(S)-epoxide 16 
in thin-layer chromatography (TLC), Was found to have the 
same con?guration as that of eponemycin epoxide. The ?nal 
coupling reaction betWeen epoxyketone 18 and dipeptide 19 
Was performed With HBTU, folloWed by removal of the 
TBDPS group and normal phase HPLC (heXanes-isopro 
panol, linear gradient, hexanes 100% to 50%) to yield dihy 
droeponemycin (3). 
As compared to prior art methods of synthetic strategies, 
the combination of Wittig-Horner and Baylis-Hillman type 
tWo-step “one-pot” reaction presented here is ef?cient and 
practical for a large quantity preparation, easily providing the 
key intermediate, hydroxymethyl-substituted enone, in a 
multi-gram scale. The one-pot reaction may be rationaliZed 
by the folloWing mechanistic consideration (Scheme 5). 
5 
20 
16 
The synthesis steps for dihydroeponemycin derivatives can 
be further reduced as the serine residue of dihydroeponemy 
cin needs to be protected and the alanine residue of its ana 
logue does not as shoW in “ToWards lmmunoproteasome 
Speci?c Inhibitors: An Important Synthesis of 
Dihydroeponemycin” Abby Ho et al., Eur. .1. Org. Chem. 
(2005), herein incorporated by reference. 
The present invention is also directed to the synthesis of 
proteasome inhibitors that selectively target the immunopro 
teasome. These proteasome inhibitors comprises a variety of 
P1'-modi?ed dihydroeponemycin analogues using easily 
available protecting groups (Scheme 6). 
Scheme 5. 
Mechanistic consideration for the one-pot reaction that may occur 
sequentially through the Wittig-Homer and Baylis-Hillman type reactions. 
BocHN 
BocHN || OMe 
O. 
‘J 
O Q 0 
i M“ i e 
O 2 
O O 1 
13 5|») 
_O 
BocHN I V 
(OM62 
O 1 
Bow 
0 
BocHN 
US 7,642,369 B2 
17 18 
Scheme 6. 
Synthetic scheme of dihydroeponernycin analogues. Reagents and conditions for 12. 
(a) 2-Methoxyethoxyrnethyl Chloride, i—Pr2EtN, CHZClZ, 0° C. —> rt; 
(b) Benzonitrile, H202, i-PrZEtN, CH3OH, 0° C., 3 h; (c) 5, TFA, CHZClZ, 30 rnin; 
(d) 7, HBTU, HoBt, i-PrZEtN, CHZClZ, rt, 12 h; (e) TBAF, THF, 1 h. 
*(e) precedes (d): 7 Was deprotected With TBAF before coupled to 6. 
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The present dihydroeponemycin analogues selectively dihydroeponemycin, in Which the P2 serine of eponemycin is 
bind to a major immunoproteasome catalytic subunit LMP2 25 replaced With alanine, displayed a non-speci?c proteasome 
and inactivate the proteolytic activity of immunoproteasome subunit binding pattern similar to that of dihydroeponemycin. 
With high speci?city. Similar competition assays Were performed to screen for 
To test the speci?city of binding of the present dihydroe- immunoproteasome inhibitors in a EL4 cell model system. 
ponemycin analogues, a screening assay Was developed for 30 EL4 cell system Was chosen since these cells highly express 
immunoproteasome subunit speci?c compounds Biotin- catalytic subunits of both the constitutive and immunoprotea 
tagged epoxomicin and dihydroeponemycin Were used as SOIneS. 
assay probes With Which to perform screening assay for Given the previous studies suggesting that the N-terminus 
immunoproteasome subunit-speci?c compounds. The hydrocarbon group plays an important role in targeting the 
screening assay Was ?rst veri?ed by using epoxomicin, dihy- 35 immunoproteasome (29), the present inhibitors Were devel 
droeponemycin and eponemycin analogue Whose protea- oped based on the derivatiZation at the C-terminal hydroxyl 
some subunit binding patterns are Well knoWn from Kim, K. group (Scheme 6). First, methoxymethyl ether (MOM) group 
B., Myung, 1., Sin, N., and CreWs, C. M. “Proteasome inhi- Was added, preparing compounds 11 and 14. This replace 
bition by the natural products epoxomicin and dihydroepone- ment caused a dramatic loss in the potency and speci?city 
mycin: insights into speci?city and potency,” Bioorg. Med. 40 compared to dihydroeponemycin (FIG. 3). Similarly, dihy 
Chem. Lett. 9, 3335-3340 (1999) (herein incorporated by droeponemycin analogues With a bulky tert-butyldiphenylsi 
reference); and “ToWards lmmunoproteasome-Speci?c lyl (TBDPS) group (10) or tetrahydropyranyl (THP) group 
Inhibitors: An Improved Synthesis of Dihydroeponemycin.” (13) lost its activity against the immunoproteasome (FIG. 3). 
Speci?cally, various concentrations of these compounds Were strikingly, When the MOM group Was replaced With meth 
pre-incubated in EL4 cells at 37° C.for 30 min. Biotin-tagged 45 oxyethoxymethyl (MEM) ether group (12), Which has a 
dihydroeponemycin or ePOXOmiCin Were then added and longer linear group than the MOM group, high speci?city 
incubated for an additional hour at 37° C. After cells Were towards LMP2 Was achieved (upper panel Of FIG 40;» 
lysed, Whole Cell lysates Were analyzed using 12% SDS' lntriguingly,Whenthebulky TBDPS group Was replacedWith 
PAGE and transferred to PVDF membranes. Biotinylated a less bulky terpbutyldimethyls?yl (TBDMS) group (15), an 
proteins Were then visualiZed using streptavidin-horseradish 50 even highgr Speci?city towards the LMP2 Subunit Was 
P?roxid?1S6 (HRP) and enhanced Chemiluminescence (ECL)- obtained, as shoWn in FIG. 4(a) (loWer panel). Preincubation 
Referring to FIG. 2(a), a Western blot Which shoWs of EL4 cells With 1 uM of compound 15 (one equivalent of 
LMP7/X and LMP2 protein bands are competed aWay by assay probe) Was suf?cient to selectively modify the catalytic 
dihydroeponemycin (2) and its analogue compound 9. FIG. threonine residue of LMP2 subunit, thereby preventing fur 
2(b) is a Western blot Which shoWs proteasome subunit (Z, 55 ther modi?cation of LMP2 subunit by biotin-dihydroepone 
MECLl, LMP7 and X) bands are ef?ciently competed aWay mycin, resulting in selective attenuation of LMP2 protein 
by excess epoxomicin. The Western blots Were performed band on Western blot. Experiments With another assay probe 
using EL4 cells pre-incubated With proteasome inhibitors for (biotin-epoxomicin), Which normally labels proteasome sub 
30 min before treating With biotinylated compounds. After 1 units LMP7, X, MECL-l and Z, further supported that both 
hr incubation, cells Were lysed, and analyZed by Western blot 60 compounds 12 and 15 speci?cally target LMP2 subunit but 
using streptavidin-HRP and ECL. not other proteasome subunits (FIG. 4(b)). These results fur 
All of biotinylated proteasome subunit bands Were equally ther Con?rm that Compounds 12 and 15 are Speci?c LMP2 
competed aWay With excess dihydroeponemycin, its ana- inhibitors 
logue or epoxomicin. These results con?rm that both The mobility shift of LMP2: l5 adduct Was investigated to 
epoximicin and dihydroeponemycin do not have speci?city 65 further verify that compound 15 covalently modi?es the 
toWards subunits of either the constitutive or immunoprotea- LMP2 subunit (FIG. 5). After EL4 cells Were incubated With 
somes. In addition to these tWo compounds, an analogue of compound 15 or assay probes (Biotin-EPX and Biotin-EPN) 
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for 1 hr at 370 C., cells Were lysed and boiled for 15 min. 
Whole cell proteins Were then analyzed by Western blot using 
anti-LMP2 antibody. In this experiment, biotinylated epoxo 
micin (Biotin-EPX) and dihydroeponemycin (Biotin-EPN) 
Were used as controls that induce LMP2 mobility shift. 
Since molecular Weights of the LMP2 subunit are 
increased by 828.08 (for biotin-epoxomicin) and 1078.45 (for 
biotin-dihydroeponemycin), assay probe-LMP2 adducts are 
expected to shoW a sloWer mobility as compared to free 
LMP2 (lanes 1-3, FIG. 5). While a sloWer mobility for the 
LMP2-15 adduct on SDS PAGE Was clearly shoWn as com 
pared to free LMP2 (lanes 4 and 5), its mobility shift Was 
smaller than those of assay probe-LMP2 adducts (lane 3 vs. 
lane 4). It can be explained by a smaller molecular Weight of 
compound 15 (484.76) compared to assay probes (828.08 and 
1078.45). Interestingly, 1 uM of compound 15 but not assay 
probes Was su?icient to modify LMP2 subunits present in 
cells (lanes 2 & 3 vs 4). This strongly indicates that compound 
15 modi?es the LMP2 subunit more e?iciently than tWo assay 
probes. LMP2 inhibitor e?iciently blocks the proteolytic 
activity of immunoproteasome With high speci?city. Screen 
ing assay and mobility shift studies have shoWn that com 
pound 15 selectively inactivates the LMP2 subunit via cova 
lent modi?cation. Since LMP2 is a major catalytic subunit 
responsible for chymotrypsin-like activity, inactivation of the 
LMP2 subunit inhibits proteolytic activity of immunoprotea 
some. Con?rmation of this is provided by enzyme kinetics 
studies performed using puri?ed 20S immunoproteasome. 
Enzyme kinetics experiments Were also carried out With the 
puri?ed 20S constitutive proteasome as control. 
TABLE 1 
Inhibition of chymotrypsin-like activity of the 20S constitutive and 
immunoproteasomes by compound 15. 
208 regular 20S Relative 
Compounds proteasome immunoproteasome selectivityC 
Epoxomicin 44,510 r 7,000 3,044 r 1,423 1 
(25-75 11M)b (100-400 11M) 
Dihydroeponemycin 721 r 84 251 r 121 5 
(0.25-5 pM) (0.5-3.0 11M) 
Compound 49 r 18 83 r 27 24 
15 (10-50 11M) (5-20 pM) 
“See Experimental Procedures for details. 
Z’Values in parentheses indicate the range of inhibitor concentrations used. 
CRelative selectivity = immunoproteasome/regular proteasome. Values are 
normalized against that of epoxomicin 
Enzyme kinetics Were performed by measuring the chy 
motrypsin-like activity of 20S immunoproteasome and regu 
lar proteasome in the presence of compound 15 using a ?uo 
rogenic peptide substrate. Although compound 15 poorly 
inhibited the chymotrypsin-like activity of 208 regular pro 
teasome, it displayed a better inhibitory activity against the 
immunoproteasome. This is quite unusual and surprising, 
considering most of proteasome inhibitors inhibit the consti 
tutive proteasome better than the immunoproteasome. More 
speci?cally, compound 15 displayed a 24-fold and 5-fold 
higher selectivity toWard the 20S immunoproteasome in com 
parison to epoxomicin and dihydroeponemycin, respectively 
(Table 1). 
Referring to FIG. 6, FIG. 6 shoWs a time- and concentra 
tion-dependent inhibition against the chymotrypsin-like 
activity of 20S immunoproteasome. All together, these results 
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provide evidence that compound 15 is a highly speci?c 
immunoproteasome inhibitor that selectively inactivates the 
LMP2 subunit. 
In conclusion, the present epoxyketone-pharrnacophore 
based selective LMP2 inhibitors inhibit the catalytic function 
of immunoproteasome With high speci?city. In addition, the 
LMP2 inhibitors inactivate the proteolytic activity of 20S 
immunoproteasome With high speci?city. 
The signi?cance of the aforementioned experiments pro 
vides evidence that the present inhibitors represent a class of 
inhibitors Which can be used as a therapeutic agent to treat 
diseases related to the immunoproteasome. The immunopro 
teasome has been implicated in a number of disease states. 
The immunoproteasome speci?c inhibitors described herein 
provide a therapeutic agent for hematological cancers, such 
as multiple myeloma, and autoimmune diseases and neuro 
degenerative diseases such as Alzheimer’s disease and Hun 
tington’s disease, as Well as provide a useful molecular probe 
to investigate the immunoproteasome biology. 
To compare the e?icacy of the present LMP2 inhibitor 
compounds and, in particular, LMP2 inhibitor 15, as com 
pared to prior knoWn inhibitors, comparative tests Were con 
ducted using compound 21 in expressing tumor cells. LMP2 
inhibitor compound 21 blocked proliferation of lung cancer 
H460, prostate cancer cells PC3 and multiple myeloma cells 
RPMI8226, as summarized in Table 2, beloW. Western blot 
analysis shoWed that the LMP2 immunoproteasome subunit 
is expressed in these cell lines. Therefore, the LMP2 inhibitor 
compounds of the present invention, based on these results, 
summarized in Tables 1 and 2, provide better or superior 
blocking of cell proliferation in cancer cells than prior LMP2 
inhibitor compounds. Thus, the present LMP2 inhibitors pro 
vide superior therapeutic agents against diseases such as 
myeloma, Alzheimer’s disease and Huntington’s disease. 
TABLE 2 
Cell proliferation assays Were performed by counting 
cell numbers after 24 h incubation With compound 21, 
dihydroeponemycin or epoxomicin 
1C MUM) 
WI-38 RPMI8226 
Cell line H460 (Lung) (Fibroblast) PC3 (Prostate) (MM) 
Compound 5 12.8 1.6 2.5 
21 
Epoxomicin 0.1 0.028 0.01 0.1 
Experiments 
The folloWing experiments Were conducted to demonstrate 
the effectiveness of the present synthesis methods for produc 
ing the dihydroeponemycin analogues. Unless otherWise 
stated, all reactions Were carried out under nitrogen With dry 
freshly distilled solvents, oven-dried glassWare and magnetic 
stirring. All solvents Were reagent graded. Tetrahydrofuran 
(THF) Was distilled from sodium/benzophenone. Methylene 
chloride (CH2Cl2) Was distilled from calcium hydride. 
Diethyl ether anhydrous Was purchased from EMD Chemi 
cals and used Without further puri?cation. All reagents Were 
purchased from Sigma-Aldrich and used Without further puri 
?cation. All reactions Were monitored by thin layer chroma 
tography (TLC) using E. Merk 60F254 pre-coated silica gel 
plates. Flash column chromatography Was performed using 
E. Merk silica gel 60 (particle size 0.040-0.063 mm) and With 
the indicated solvents. 1H and Was recorded in CDCl3 using a 
Varian 300 MHz spectrometer at ambient temperature using 
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an internal deuterium lock unless stated otherwise. Chemical 
shift are referenced to residual chloroform (6:7.27 ppm for 
1H). High and loW resolution mass spectra Were carried out by 
the University of Kentucky Mass Spectrometry Facility. 
Synthesis of compound 12 is described here as the repre 
sentative synthetic procedure for all dihydroeponemycin ana 
logues and, as described in “Development of the lmmunopro 
teasome-Speci?c Inhibitors,” Abby Ho and Kyung-Bo Kim, 
[Journal Name] (200_), herein incorporated by reference. 
Such analogues include those of formula (I). 
(4S)-4-(tert-butoxycarbonyl)-amino-2-hydroxy-methyl 
6-methylhept-1-en-3-one (3): Synthetic procedures Were per 
formed as previously reported in Fruh, K., Gossen, M., Wang, 
K., Bujard, H., Peterson, P. A., and Yang, Y. (1994), herein 
incorporated by reference. Displacement of housekeeping 
proteasome subunits by MHC-encoded LMPs: a neWly dis 
covered mechanism for modulating the multicatalytic pro 
teinase complex. Embo. J. 13, 3236-3244. 
(4S)-4-(tert-Butoxycarbonyl)-amino-2-(methoxy 
ethoxymethoxymethyl)-6-methylhept-1-en-3-one (4): To a 
solution of compound 3 (114 mg, 0.42 mmol) in CH2Cl2 (5 
ml) at 0° C. Was added methoxyethoxymethyl chloride (0.24 
ml, 2.1 mmol) and diisopropylethylamine (0.37 ml, 2.1 
mmol). After stirring at room temperature for 3 h, the result 
ing mixture Was pour into ice Water (20 ml) and extracted With 
CH2Cl2 (3x20 ml). The organic layers Were combined, 
Washed With brine (20 ml), dried With Na2SO4, ?ltered and 
concentrated under reduced pressure. The product Was then 
subjected to ?ash column chromatography (hexane/EtOAc, 
5:1) yielding compound 4 (101 mg, 67%) as a yelloWish oil. 
1H NMR: 6:6.20 (d, 21:318 HZ, 2H, 1-H), 5.12 (d, 21:90 
HZ, 1H, NH), 5.03 (m, 1H, 4-H), 4.75 (s, 2H, 2-OCH2O), 4.28 
(s, 2H, 2-CH2), 3.69 (m, 2H, 2-OCH2CH2O), 3.55 (m, 2H, 
2-OCH2CH2O), 3.38 (s, 3H, 2-OCH3), 1.74 (m, 1H, 6-H), 
1.50 (m, 1H, 5-H“), 1.41 (s, 9H, HBOC), 1.31 (m, 1H, 5-Hb), 
0.99 (d, 31:66 HZ, 3H, CH3CHCH3), 0.90 (d, 31:66 HZ, 3H, 
CH3CHCH3) ppm. 
(2RS,4S)-4-(tert-Butoxycarbonyl)-amino-2-(methoxy 
ethoxymethoxymethyl)- 6-methyl -1 ,2 -oxiranyl-heptane (5, 
5'): BenZonitrile (0.29 ml, 2.8 mmol), H2O2 (0.40 ml, 50% 
solution in H2O, 7.0 mmol) and diisopropylethylamine (0.5 
ml, 2.8 mmol) Were added to a solution of compound 4 (100 
mg, 0.28 mmol) in MeOH (5 ml) at 0° C. The reaction Was 
stirred at 0° C. for 3 h. The resulting mixture Was then con 
centrated under reduced pressured and subjected to ?ash col 
umn chromatography (hexane/EtOAc, 10:1) to yield com 
pounds 5 and 5' With a ratio of 3:1 (60 mg, 60%). Compound 
5: 1H NMR: 6:4.82 (d, 21:84 HZ, 1H, NH), 4.71 (s, 2H, 
2-OCH2O), 4.39 (d, 2J:11.4 HZ, 1H, 2-CH“2), 4.32 (m, 1H, 
4-H), 3.68 (m, 2H, 2-OCH2CH2O), 3.57 (m, 2H, 
2-OCH2CH2O), 3.49 (d, 2J:11.4 HZ, 1H, 2-CHZ’2), 3.40 (s, 
3H, 2-OCH3), 3.27 (d, 21:48 HZ, 1H, 1-H“), 3.03 (d, 21:48 
HZ, 1H, l-Hb), 1.75 (m, 1H, 6-H), 1.58 (m, 1H, 5-H“), 1.41 (s, 
9H, HBOC), 1.13 (m, 1H, 5-H°), 0.97 (d, 31:66 HZ, 3H, 
CH3CHCH3), 0.94 (d, 31:66 HZ, 3H, CH3CHCH3) ppm. 
(S)iO-tert-Butyidiphenylsiloxymethyl-N-heptanoyl 
serine (7): Lithium hydroxide (91 mg, 3.8 mmol) Was added 
to a solution of (S)4O-tert-Butyldiphenyl-siloxymethyl-N 
heptanoyl-seryl methyl ester (890 mg, 1 .8 mmol) in methanol 
Water (3:1) solution. Reaction Was stirred at 50 C. for 15 h. 
Resulting mixture Was poured into H2O With cold 1N HCl and 
extracted With CH2Cl2. The organic layers Were combined, 
Washed With brine, dried under Na2SO4, ?ltered, concen 
trated and dried under high vacuum. The product obtained 
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yielded compound 7 as yelloWish oil. 1H NMR: 6:7.61 (m, 
4H, AriH), 7.41 (m, 6H, AriH), 6.24 (d, 21:75 HZ, 1H, 
NH), 4.69 (m, 1H, 2-H), 4.17 (dd, 21:104 HZ, 21:36 HZ,1H, 
3-H“), 3.89 (dd, 21:104 HZ, 21:36 HZ, 1H, 3-Hb), 2.20 (t, 
31:75 HZ, 2H, 2'-H), 1.60 (m, 2H, HHeP), 1.29 (m, 6H, HHeP), 
1.05 (s, 9H, Hbutyl), 0.88 (t, 31:69 HZ, 3H, 7'-CH3) ppm. 
(S)iO-tert-Butyidiphenylsiloxymethyl-N-heptanoyl 
seryl methyl ester: tert-Butyldiphenylsilyl chloride (1.95 ml, 
7.6 mmol), imidaZole (519 mg, 7.6 mmol) Was added to a 
solution of (S)-N-heptanoyl-serine methyl ester (588.6 mg, 
2.5 mmol) in CH2Cl2 (20 ml) and stirred overnight at room 
temperature. The resulting mixture Was concentrated under 
reduced pressure and subjected to column chromatography 
(hexane/EtOAc, 5:1) yielding (S)4O-tert-Butyldiphenylsi 
loxymethyl-N-heptanoyl-seryl methyl ester (890 mg, 74%) 
as colorless oil. 1H NMR: 6:7.59 (m, 4H, AriH), 7.41 (m, 
6H,AriH), 6.28 (d, 21:84 HZ, 1H, NH), 4.70 (m, 1H, 2-H), 
4.12 (dd, 21:101 HZ, 21:30 HZ, 1H, 3-H“), 3.89 (dd, 21:101 
HZ, 21:30 HZ, 1H, 3-Hb), 3.74 (s, 3H, 1-OCH3), 2.11 
(t, 3J:7.7 HZ, 2H, 2'-H), 1.57 (m, 2H, HHeP), 1.30 (m, 6H, 
HHeP), 1.04 (s, 9H, Hbmyl), 0.88 (t, 31:67 HZ, 3H, 7'-CH3) 
ppm 
(S)iN-heptanoyl-serine methyl ester: To a solution of 
heptanoic acid (0.46 ml, 3.2 mmol) and H-Ser-OCH3 (0.5 g, 
3.2 mmol) in CH2Cl2 (15 ml) Were added HBTU (1.83 g, 4.8 
mmol), HOBt (0.74 g, 4.8 mmol) and lastly diisopropylethy 
lamine (2.8 ml, 16 mmol). Reaction Was stirred overnight at 
room temperature. The resulting mixture Was subjected to 
?ash column chromatography (hexane/EtOAc, 1:2) yielding 
(S)iN-heptanoyl-serine methyl ester (588.6 mg, 79%) as 
yelloWish oil. 1H NMR: 6:6.47 (b, 1H, NH), 4.69 (m, 1H, 
2-H), 3.94 (m, 2H, 3-H), 3.79 (s, 3H, 1-OCH3), 2.27 (t, 31:76 
HZ, 2H, 2'-H), 1.63 (m, 2H, HHeP), 1.29 (m, 6H, HHeP), 0.88 
(m, 3H, 7'-CH3) ppm. 
(4S)-2-methoxyethoxy-methoxymethyl-4-[(S)iO-tert 
butyidiphenylsiloxy-methyl-N-heptanoylseryl-amino] -6 
methyl-1,2-oxiranyl-heptane: Tri?uoroacetic acid (100 pl, 
0.87 mmol) Was added to a solution of compound 5 (45 mg, 
0.12 mmol) in CH2Cl2 (0.5 ml) at room temperature for 30 
min. Subsequently, the concentrated mixture Was dried under 
high vacuum to remove tri?uoroacetic acid. The resulting 
crude product 6 (33 mg, ca. 100%) Was then used in the 
folloWing coupling reaction Without further puri?cation. To a 
solution ofproduct 6 (33 mg, 0.12 mmol) and 7 (65 mg, 0.14 
mmol) in CH2Cl2 (5 ml) Were added HBTU (68 mg, 0.17 
mmol), HOBt (27 mg, 0.17 mmol) and lastly diisopropylethy 
lamine (104 pl, 0.59 mmol). Reaction Was stirred overnight at 
room temperature. The resulting mixture Was subjected to 
?ash column chromatography (hexane/EtOAc, 3:1) to give 
(4S)-2-methoxyethoxy-methoxymethyl-4-[(S)4O-tert-bu 
tyldiphenylsiloxy-methyl-N-heptanoylseryl-amino] -6-me 
thyl-1,2-oxiranyl-heptane (36 mg, 42%). 1H NMR: 6:7.71 
(m, 4H,AriH), 7.44 (m, 6H,AriH), 7.02 (d, 21:84 HZ, 1H, 
4-NH), 6.17 (d, 21:66 HZ, 1H, 2'-NH), 4.72 (s, 2H, 
2-OCH2O), 4.60 (m, 2H, 4-H, 2'-H), 4.42 (d, 21:1 1 .4 HZ, 1H, 
2-CHa2), 4.03 (m, 1H, 3'-H“), 3.70 (m, 3H, 3'-CH°2, 
2-OCH2CH2O), 3.55 (m, 2H, 2-OCH2CH2O), 3.52 
(d, 2J:11.4 HZ, 1H, 2-CHb2), 3.40 (s, 3H, 2-OCH3), 3.29 
(d, 21:54 HZ, 1H, 1-H“), 3.04 (d, 21:48 HZ, 1H, l-Hb), 2.13 
(t, 31:76 HZ, 2H, 2"-H), 1.63 (m, 4H, 6-H, 5-H“, HHeP), 1.26 
(m, 6H, HHeP), 1.07 (s, 9H, 3'-tBu), 0.96 (d, 31:63 HZ, 3H, 
CH3CHCH3), 0.91 (d, 31:63 HZ, 3H, CH3CHCH3), 0.86 
(t, 3J:7.6 HZ, 3H, 7"-CH3) ppm. 
(4S)-2-methoxyethoxymethoxymethyl-4-N-hep 
tanoylserylamino-6-methyl-1,2-oxiranylheptane (12): To a 
solution of (4S)-2-methoxyethoxy-methoxymethyl-4-[(S)i 
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O-tert-butyldiphenylsiloXy—methyl-N-heptanoylseryl 
amino]-6-methyl-1,2-oXiranyl-heptane (30 mg, 0.042 mmol) 
in THF (1 ml), tetrabutylammonium ?uoride (50 ul, 1 M in 
THF, 0.05 mmol) Was added. Reaction Was stirred at room 
temperature for 1 hour, followed by ?ash column chromatog 
raphy (heXane/EtOAc, 1:2) yielding compound 12 (16 mg, 
80%) as yellowish oil. 1H NMR: 6:6.83 (d, 2J:7.5 HZ, 1H, 
4-NH), 6.44 (d, 21:75 HZ, 1H, 2'-NH), 4.71 (s, 2H, 
2-OCH2O), 4.50 (m, 2H, 4-H, 2'-H), 4.41 (d, 21:1 1.7 HZ, 1H, 
2-CH“2), 4.08 (m, 1H, 3'-H“2), 3.68 (m, 2H, 2-OCH2CH2O), 
3.55 (m, 3H, 2-OCH2CH2O, 3'-Hb2), 3.46 (d, 21:1 1 .7 HZ, 1H, 
2-CHb2), 3.40 (s, 3H, 2-OCH3), 3.27 (d, 2J:5.1 HZ, 1H, 
1-H“), 3.05 (d, 21:48 HZ,1H, l-Hb), 2.22 (m, 2H, 2"-H), 1.60 
(m, 4H, 6-H, 5-H“, HHeP), 1.28 (m, 6H, HHeP), 0.96 (d, 31:39 
HZ, 3H, CH3CHCH3), 0.94 (d, 31:39 HZ, 3H, CH3CHCH3), 
0.88 (t, 31:67 HZ, 3H, 7"-CH3) ppm. MS (ESI): m/Z:475, 
calcd. for C23H42N2O8: m/Z:474.59. 
Cell Culture and Screening As say: Murine lymphoma EL4 
(ATCC) cells Were groWn in RPMI medium (Gibco), 10% 
fetal bovine serum and 1% penicillin and streptomycin at 00 
C. in a 5% CO2 incubator. Cells Were pretreated With 1 uM 
biotinylated compounds 30 minutes prior to the addition of 
increasing concentrations of either dihydroeponemycin, 
epoxomicin or dihydroeponemycin analogues as indicated. 
The cells Were then incubated for an additional 1 hour. Cell 
lysates Were analyZed by 12% SDS-PAGE and transferred to 
PVDF membrane. Proteins that Were covalently modi?ed by 
biotinylated compounds Were visualiZed by enhanced chemi 
luminescence using streptavidin conjugated horseradish per 
oxidase (Sigma-Aldrich) or anti-LMP2 (A?inity 
BioReagents) and Biomax X-ray ?lm (Kodak). 
Enzyme Kinetic Studies: kaSSOcZ-an-On values Were determined 
as folloWs. Inhibitors Were mixed With a ?uorogenic peptide 
substrate and assay buffer [20 mM Tris (pH 8.0), 0.5 mM 
EDTA, and 0.035% SDS] in a 96-Well plate. The chymot 
rypsin-like activity Was assayed using the ?uorogenic peptide 
substrates Suc-Leu-Leu-Val-Tyr-AMC (Sigma-Aldrich). 
HydrolysisWas initiated by the addition of bovine 20S pro 
teasome or immunoproteasome (Biomol International), and 
the reaction Was folloWed by ?uorescence (360-nm excita 
tion/460-nm detection) using a Microplate Fluorescence 
Reader (FL600; Bio-Tek Instruments, Inc., Winnoski, Vt.) 
employing the softWare KC4 v.2.5 (Bio-Tek Instruments, 
Inc., Winooski, Vt.). Reactions Were alloWed to proceed for 
60-90 min, and ?uorescence data Were collected every 1 min. 
Fluorescence Was quanti?ed as arbitrary units and progres 
sion curves Were plotted for each reaction as a function of 
time. kobserved/[l] values Were obtained using PRISM pro 
gram by nonlinear least squares ?t of the data to the folloWing 
equation: ?uorescenceqlst+[(vo—vs)/kobserved] 
[1-exp(—k0bserved t)], Where v0 and vs are the initial and ?nal 
velocities, respectively, and kobserved is the reaction rate con 
stant. The range of inhibitor concentrations tested Was chosen 
so that several half-lives could be observed during the course 
of the measurement. Reactions Were performed using inhibi 
tor concentrations that Were <100-fold of those of the protea 
some assayed. 
The invention claimed is: 
1. A method for synthesizing a hydroXymethyl-sub stituted 
enone, comprising the steps: 
(a) reacting Boc-Leu-OMe With dimethyl methylphospho 
nate treated With tert-butyllithium to form the com 
pound, 
20 
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/OCH3 
and 
O 
(b) adding CH2O and K203 to the product of step (a) and 
alloWing the reagents to react to produce the hydroxym 
ethyl-sub stituted enone, 
BocNH 
O OH. 
2. The method of claim 1, Wherein said step (a) comprises 
cooling dimethyl methylphosphonate treated With tert-butyl 
lithium in THF at —780 C. prior to adding the Boc-Leu-OMe. 
3. The method of claim 1 further comprising: 
(c) adding TBDMSCl, ImidaZole and CH2Cl2 to the 
hydroxymethyl-substituted enone from step (b); 
(d) adding benZonitrile, H202, i-PrzEtN and CH3OH; 
(e) adding TFA and CH2Cl2; 
(f) adding 
NH 
OH 
0 \OTBDPS, 
HBTU, HoBt, i-PR2EtN and CH2Cl2, folloWed by TBAF 
and THF to produce dihydroeponemycin, 
NH 
O OH. 
4. The method of claim 3, Wherein said step (f) comprises 
adding 
NH 
OH 
0 \OTBDPS, 
HBTU, HoBt, i-PR2EtN and CH2Cl2 at room temperature for 
12 hours before adding the TBAF and THF. 
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5. A Pl‘ modi?ed dihydroeponemycin analogue compris 
ing a compound having the structure of formula I, 
28 
o o 
(I) 
a O a a 5 O/\O/ O/\O/\/ \ U
o 
o NWNHA O O = NH 10 ii ii = / \, or Ph/ \Ph 
0 R1 0 R2, + + I 
Where: 
R1 is CH3 or CH3OH; and 15 
R2 is OH, 7. The method of claim 6, further comprising (e) prior to 
step (d), adding TBAF and THF to the product of step (c). 
O O 8. A method for treating disease by administering to a 
7 O 7 , ~ ~ ~ . - 
OAO/ O/\O/\/ \ 20 patient an effective amount of a dihydroeponemycm ana 
logue having the formula I, 
O O 
i- ' l 
/ \. or Ph/ \Ph <1) 
25 
6. A method for manufacturing a P1‘ modi?ed dihydroe- O O 
ponemycin analogue, comprising: NHA 
(a) reacting a hydroxymethyl-substituted enone, 30 ANY 5 NH 
0 Ii} 0 R2, 
Where: 
35 R1 is cH3 or CH3OH; and 
BocNH R2 is OH’ 
0 OH, 
with 2-Methoxyethoxymethyl chloride, i-PrZEtN, 40 O O 
CH2Cl2, from 0° C. to rt; , O , , 
(b) adding benZonitrile, H202, i-PrZEtN, CH3OH; O/\O/ O/\O/\/ \ 
(c) adding TFA, CH2Cl2; and 
(d) adding HBTU, HoBt, i-PrZEtN, CH2Cl2; and 
45 O O 
O i L l 1 
NH / \, Or Ph/ \Ph, 
5 0H, 
0 50 
to produce P1‘ modi?ed dihydroeponemycin analogue’ to bind to the LMP2 subunit of the immunoproteasome, 
havmg formula I thereby treating the disease. 
(I) 55 9. The method of claim 7, wherein R1 is CH3 and R2 is 
O 
o | 
A O NH 60 
W NH 0 0 R2, + 
Where: 
R1 is CH3 or CH3OH; and 
R2 is OH, 
Zen-nu 
65 10. The method of claim 7, Wherein the disease is selected 
from the group consisting of myeloma, AlZheimer’s disease, 
and Huntington’s disease. 
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11. The method of claim 9, wherein R1 is CH3 and R2 is 
O 
Si 5 
12. The method of claim 8, Wherein said administering 
comprising administering the dihydroeponemycin analogue 
via intravenous administration. 
13. A method of inactivating enzymatic activity of the 
LMP2 subunit of the immunoproteasome, comprising: 
administering to a patient in need of treatment thereof, an 
effective amount of a dihydroeponemycin analogue of 
formula I, 
15 
O 
O 25 
NH 
WY NH 
0 R2, 26-- ml O 
30 
Where: 
R1 is CH3 or CH3OH; and 
R2 is OH 
0 o 
a O a , O/\O/ O/\O/\/ \ U
o 0 
S1 S1 
as, or Plx’h, 
to bind to LMP2 of the immunoproteasome, to thereby 
inactivate the immunoproteasome. 
14. The method of claim 13, wherein R1 is CH3 and R2 is 
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